Pulmonary dysfunction following TAAA repair remain the leading cause of postoperative morbidity and mortality occurring in 20%-40% of patients (29).
Cardiac complications, including perioperative myocardial infarction and cardiac death, are estimated to occur in 10%-15% of TAAA repairs (33, 34).
TAAA repair is associated with major blood losses, often exceeding the patient's intravascular volume.
The primary aim of open TAAA repair is to minimise the ischaemic time to vital organ system.
Cerebrospinal fluid drainage substantially reduces the risk of paraplegia in patients undergoing TAAA repairs, particularly extents I, II and possibly III (45).
Heparin is primarily used to prevent stasis-induced thrombosis of small vessels during the clamp period of TAAA repair.
A devastating complication of TAAA repair is paraplegia, with incidences ranging from 2.7%-20% (51, 52).
Although there is a clear benefit of CSF drainage in patients undergoing TAAA repair, it is not without risks.
The extent of TAAA repair has prognostic significance with respect to intraoperative blood loss and coagulopathy.
In the current study, we present the early and midterm results associated with the usage of MFM, which is used in treating the patients diagnosed with TAAA and IAA.
While custom-made fenestrated stent grafts were used in some studies of TAAA with branches, the multilayer flow modulator has also been used in such pathologies [21-26].